- Our Doctors
- Dr John Park
Dr John Park
MBBS BSc (Med) MPH FRACP PhD, Medical Oncologist
Languages spoken
English, Korean
Overview
Centres
Clinical interests
Special clinical interest in breast, skin (melanoma) and head and neck cancers.
Dr Park completed his Medical Oncology training at Westmead, Nepean, Blacktown and Orange hospitals. He undertook a further fellowship in melanoma as a clinical trials fellow at Westmead Hospital affilicated with Melanoma Institute Australia. John was awarded Fellow of the Royal Australasian College of Physicians in 2017. John is appointed at Nepean Hospital as a Staff Specialist.
John is passionate about clinical trials and currently leads Phase 1 clinical trials at Macquarie University. He has extensive experience in phase 1 - 3 clinical trials in adult solid tumours.
John completed Masters of Public Health at University of Sydney and was awarded his PhD at Macquarie University in 2023, titled “Oncogenic Signaling in Uveal Melanoma”. He is a Conjoint Senior Lecturer at Macquarie University and a Clinical Lecturer at University of Sydney.
In his spare time, John enjoys outdoor sports, travelling and spending time with his family.
Clinical interests
John’s research interests include basic and translational research.
Professional memberships
- American Society of Clinical Oncology (ASCO)
- European Society for Medical Oncology (ESMO)
- Medical Oncology Group of Australia (MOGA)
- Thoracic Oncology Group of Australasia (TOGA)
Publications
- Yao, H., Yan, M., Tong, Z., Wu, X., Ryu, M. H., Park, J. J., ... & Song, E. (2024). Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial. Journal of Clinical Oncology, JCO-23.
- Smith-Uffen, M., Park, J., Parsonson, A., Kiely, B. E., & Vasista, A. (2024). Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy. The Oncologist.
- Park, J. J., Hamad, S. A., Stewart, A., Carlino, M. S., Lim, S. Y., & Rizos, H. (2024). PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma. Oncogenesis, 13(1), 9.sdf
- Park, J. J., Diefenbach, R. J., Joshua, A. M., Kefford, R. F., Carlino, M. S., & Rizos, H. (2018). Oncogenic signaling in uveal melanoma. Pigment cell & melanoma research, 31(6), 661-672.
- Parakh, S., Park, J. J., Mendis, S., Rai, R., Xu, W., Lo, S., ... & Carlino, M. S. (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British journal of cancer, 116(12), 1558-1563.
- Sabanathan, D., Park, J. J., Marquez, M., Francisco, L., Byrne, N., & Gurney, H. (2017). Cure in advanced renal cell cancer: is it an achievable goal?. The Oncologist, 22(12), 1470-1477.
- Park, J. J., Boddy, A. V., Liu, X., Harris, D., Lee, V., Kefford, R. F., & Carlino, M. S. (2017). Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment Cell & Melanoma Research, 30(1), 68-71.
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.